Author

Barbara Martins Da Costa

Institute of Cancer ResearchORCID 0000-0002-8993-6790Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:human· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

Louis ChesleriD· 3 shared Federica LorenziiD· 2 shared Kevin GreensladeiD· 2 shared Sally L. GeorgeiD· 2 shared Vidur TandoniD· 2 shared Andrea LampisiD· 1 shared Angela BelliniiD· 1 shared Anke M. NijhuisiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Louis CheslerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A COJEC-chemotherapy resistant model of Th-ALK(F1174L)/MYCN neuroblastoma offers insights into tumour immune evasion and development of the bone marrow metastatic niche

Elizabeth R. Tucker, Andrea Lampis, Jacob Househam, Duncan Roberts, Karen T. Barker, Barbara Martins Da Costa, Kevin Greenslade, Sarah Mayfield, Federica Lorenzi, Emma Thorley, Vidur Tandon, Nan Sophia Han, Giulia Emanuelli, Marwane Bourdim, Georgia Martin, , Louis Chesler

This study develops a neuroblastoma mouse model to investigate chemotherapy resistance and immune evasion mechanisms, identifying CDK8 upregulation and immune cell infiltration as key factors.

bioRxiv · Sep 2, 2026 · PreprintCancer Biology

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders

Yurui Ma, Evon Poon, Chenchen Jin, Barbara Martins Da Costa, Yuewei Xu, Sadiya Quazi, Nikolaos Zourdoumis, Chiharu Wickremesinghe, Louis Chesler, Hector C. Keun, Anke M. Nijhuis

This paper combines RBM39 degradation and SRPK1 inhibition to disrupt RNA splicing in neuroblastoma, showing synergistic anti-cancer effects in cell lines and a mouse model.

Cell Reports · Jan 1, 2026Peer-reviewedCancer Biology

Differential chromatin response to retinoic acid in neuroblastoma according to type of ATRX mutation

Federica Lorenzi, Matthew Shipley, Luke Deane, Robert J. Goldstone, Vidur Tandon, Barbara Martins Da Costa, Kevin Greenslade, Karen Louise Barker, Fariba Némati, Angela Bellini, Gudrun Schleiermacher, Louis Chesler, François Guillemot, Sally L. George

This study shows that ATRX mutation type affects chromatin response to retinoic acid in neuroblastoma, influencing differentiation and therapeutic response.

Neoplasia · Dec 11, 2025Peer-reviewedCancer Biology